Learn the evidence, TAME trial status, B12 and muscle risks, and who should talk to a doctor before using metformin for longevity.
Metformin is not an anti-aging shortcut. It is a proven diabetes drug with credible longevity biology, but the case for healthy adults is still unproven. The right question is not “does metformin extend life?” The useful question is: who might benefit, who could be harmed, and what should be measured first?
This guide reviews the evidence on metformin for longevity, including plausible benefits, TAME trial status, side effects, muscle and B12 concerns, and when a doctor-led biomarker review makes more sense than self-medication.
TL;DR: metformin longevity benefits and safety in 2026
Medical caveat: metformin makes strong medical sense in type 2 diabetes, prediabetes, and insulin resistance. As a longevity drug for metabolically healthy people, the evidence still does not justify self-medication.
- Most plausible benefit: better glucose and insulin control when metabolic risk is present.
- Main uncertainty: no completed trial proves longer healthspan in healthy adults.
- Main safety checks: kidney function, vitamin B12, GI tolerance, medication interactions, and exercise goals.
- Best next step: review HbA1c, fasting insulin, body composition, muscle status, and lifestyle fundamentals before discussing a prescription.
Key evidence to know: the TAME trial rationale explains why metformin is being tested for aging biology, while the MASTERS trial and MET-PREVENT trial are reminders that biomarkers do not always translate into better strength or function.
| Situation | What we know | Prudent decision |
|---|---|---|
| Type 2 diabetes or prediabetes | Proven metabolic benefit; lowers diabetes progression in higher-risk profiles | Discuss with a physician and biomarkers |
| Normal metabolism and strength training | No proven clinical longevity benefit; may blunt muscle adaptations | Prioritize strength, protein, sleep, and follow-up |
| Frailty or sarcopenia | MET-PREVENT 2025 did not improve walking speed and was poorly tolerated | Do not use it as a sarcopenia treatment |
| Anti-aging interest without medical indication | TAME has no published efficacy results yet | Wait for data; track HbA1c, insulin, B12, and kidney function |
What metformin is and why it is studied for longevity
Metformin belongs to the biguanide class of drugs. Its origin traces back to Galega officinalis (French lilac), a plant used for centuries in Europe for symptoms we now recognize as diabetes. It was approved in the UK in the 1950s and by the FDA in 1995. Today it is the most widely prescribed antidiabetic drug on the planet, with over 150 million users.
The interest in longevity came from an unexpected observation. Several epidemiological studies found that people with diabetes treated with metformin had lower all-cause mortality than people without diabetes. It was as if the medicated patient outlived the healthy reference group. This set the scientific community alight: could metformin do something beyond blood sugar control?
Dr. Ángel Durántez, a leading longevity medicine physician in Spain, has repeatedly highlighted that carbohydrate metabolism — how we process glucose — is one of the pillars of aging. If metformin modulates this metabolism, there is biological logic in exploring its geroprotective potential.
How metformin works at the molecular level
Metformin does not have a single mechanism of action. It is described as a "dirty" drug (in a biochemical sense): it acts on multiple cellular targets simultaneously. Here are the main ones:
1. AMPK activation
AMPK (AMP-activated protein kinase) is the cell's "energy sensor." When ATP levels drop (the cell has less energy), AMPK activates and triggers conservation and recycling processes. Metformin inhibits Complex I of the mitochondrial electron transport chain, reducing ATP production and indirectly activating AMPK.
AMPK activation has an effect compared to caloric restriction: it inhibits mTOR, stimulates autophagy (cellular cleanup), and improves insulin sensitivity. In fact, many of the metabolic benefits of intermittent fasting come from activating this pathway. You can read more about this in our article on intermittent fasting and autophagy.
2. mTOR inhibition
mTOR (mechanistic target of rapamycin) is a protein that promotes cell growth. When overactivated — common with high-protein, high-sugar diets and with aging — it accelerates cellular aging. Metformin, through AMPK, partially inhibits mTORC1, damping that excessive growth signal.
This mechanism shares similarities with rapamycin and sirtuins, other pharmacological targets active in the longevity field.
3. Reduced inflammation and DNA damage
Metformin reduces inflammatory markers like C-reactive protein (CRP) and NF-κB factor. It also decreases mitochondrial reactive oxygen species (ROS) production and protects against DNA damage. These effects connect directly to inflammaging, the chronic low-grade inflammation that accompanies aging and is one of the 12 hallmarks of aging.
4. Glucose metabolism effects
Metformin reduces hepatic glucose production (gluconeogenesis) and improves insulin sensitivity in muscle and liver. This means the body needs less insulin to process carbohydrates. Less circulating insulin is associated with reduced activation of growth pathways (like IGF-1) that accelerate cellular aging.
| Mechanism | Cellular effect | Longevity relevance |
|---|---|---|
| AMPK activation | Mimics caloric restriction: energy conservation, autophagy | Strong evidence in animal models |
| mTORC1 inhibition | Dampens excessive cell growth | Same mechanism as rapamycin |
| Inflammation reduction | Lowers CRP, NF-κB, pro-inflammatory cytokines | Connected to inflammaging |
| Insulin sensitivity improvement | Less insulin, less IGF-1 | Fewer cellular aging signals |
| Mitochondrial Complex I inhibition | Less ROS, less oxidative damage | DNA and mitochondrial protection |
Current scientific evidence: what is proven and what is not
This is where we need to keep our feet on the ground. The evidence on metformin and longevity has layers, and not all carry the same weight.
Observational data: promising but biased
The study that started it all was Bannister et al. (2014), which analyzed over 78,000 diabetic patients treated with metformin monotherapy and found they had lower all-cause mortality than non-diabetic controls. A striking finding.
The problem: the metformin group consisted of healthier diabetics (those not requiring additional drugs), while non-diabetic controls may have included people with undiagnosed conditions. Also, the benefit disappeared in those over 60. A subsequent meta-analysis by Campbell et al. (2017) confirmed the trend but with the same methodological limitations.
In 2022, a Danish study (Keys et al.) failed to replicate Bannister's results: metformin users showed higher mortality than non-diabetics. And in 2025, a review titled "Emerging uncertainty on the anti-aging potential of metformin" pointed out that selection bias (comparing diabetics with "never-diabetics" who are often cardiovascular patients) artificially inflates control-group mortality.
Observational verdict: there is a biologically plausible signal, but the data does not allow us to conclude that metformin extends life in healthy people.
Clinical trials in humans: disappointing results
Several controlled trials have evaluated metformin in non-diabetic people, focusing on aging biomarkers and physical function:
- MILES Study (2016-2019): Metformin modified aging-related gene expression in non-diabetic people, but did not measure long-term clinical outcomes (Konopka et al., 2019, Aging Cell).
- MASTERS Trial (2019): Metformin reduced muscle mass gains after a resistance training program in older adults. A relevant adverse effect, given that sarcopenia is a mortality risk factor (Walton et al., 2019, Aging Cell).
- MET-PREVENT Trial (2025): Published in The Lancet Healthy Longevity, this randomized trial included 72 older adults (mean age: 80 years) with probable sarcopenia and pre-frailty or frailty. They took 500 mg of metformin three times daily for 4 months. Four-meter walking speed did not improve versus placebo (adjusted difference: 0.001 m/s; p=0.96), and tolerability was worse, with more adverse events and hospital admissions (Witham et al., 2025, PMID: 40147475).
Clinical verdict: metformin modifies molecular pathways related to aging, but this does not translate (yet) into measurable functional improvements in healthy people.
The macaque study (2024): the data point that revived the debate
In September 2024, a Chinese team published in Cell a 40-month study with cynomolgus monkeys (Yang et al., PMID: 39270656). They administered metformin at 20 mg/kg/day and evaluated 68 biological parameters. The results were striking:
- A reduction of ~6 years in biological brain age (based on DNA methylation clocks).
- Preserved cortical thickness, especially in the frontal lobe.
- Improved short-term memory and cognitive flexibility scores.
- Reduced inflammatory markers and cellular aging markers across multiple tissues.
However, the study has important limitations: the monkeys were obese and possibly diabetic (no baseline glucose data was published), there was no pre-study health data, and the epigenetic clock was validated on a small sample. Coleen Murphy, a longevity researcher at Princeton, summarized it in an interview: "Everyone in the longevity field takes metformin," but the evidence in healthy humans remains insufficient.
Preclinical verdict: the primate study is the most solid to date in animal models close to humans, but it does not demonstrate efficacy in healthy people. It is a reason to keep researching, not to self-medicate.
The TAME trial: the definitive test (pending)
The TAME (Targeting Aging with Metformin) trial is a clinical study designed by Nir Barzilai at the Albert Einstein College of Medicine. AFAR's official resource describes it as a six-year series of trials across 14 sites, with Wake Forest University School of Medicine as the coordinating center and more than 3,000 adults aged 65-79. The goal is to test whether metformin delays the development or progression of age-related diseases: cardiovascular disease, cancer, dementia, and mortality.
The important nuance: as of 2026, no efficacy results have been published. AFAR still presents TAME as a prepared design that needs funding for full launch. If completed with positive results, it would be the first trial to treat aging as a medical indication, not just a risk factor. Until then, any claim that TAME has already proven metformin slows aging is ahead of the data.
Potential longevity benefits by system
Metabolism and glucose
Metformin's metabolic effect is beyond question. It improves insulin sensitivity, reduces HbA1c, and decreases hepatic gluconeogenesis. In people with insulin resistance or prediabetes, these effects are clearly beneficial. The Diabetes Prevention Program demonstrated that metformin reduces type 2 diabetes incidence by 30% in people with prediabetes.
For people with normal metabolism, the additional benefit is uncertain. Metabolic biomarkers like HbA1c, HOMA-IR, and fasting glucose should guide the decision, not speculation.
Brain and cognition
The macaque study suggests neuroprotection, and some observational data in humans indicates lower risk of cognitive decline in metformin users. But the data is inconsistent: other studies have found no effect, and there is some concern that metformin could worsen cognition in people with established cognitive impairment and low vitamin B12 levels.
The TAME trial will include cognitive assessments, which could clarify this question in the coming years.
Inflammation and cellular aging
Metformin reduces chronic low-grade inflammation — the inflammaging that drives much of age-related deterioration. It also appears to reduce the burden of senescent cells and their secretory phenotype (SASP), though with less potency than specific senolytics. For a full-spectrum anti-inflammatory strategy, anti-inflammatory nutrition remains the best-supported intervention.
Side effects and who should NOT take metformin
Metformin has a reasonable safety profile, but it is not harmless. Here are the most relevant adverse effects:
| Adverse effect | Frequency | Notes |
|---|---|---|
| GI issues (nausea, diarrhea) | 20-30% of users | Usually improves over time; take with food |
| Vitamin B12 deficiency | 6-10% with long-term use | Requires monitoring; can cause neuropathy |
| Reduced muscle gain from exercise | Documented in MASTERS (2019) | Interferes with resistance training adaptations |
| Lactic acidosis (rare) | <0.1% but potentially fatal | Real risk in severe kidney failure |
| Drug interactions | Variable | Review with doctor; affects iodinated contrast, alcohol |
Do NOT take metformin without medical supervision if you have:
- Moderate-to-severe kidney failure (eGFR < 30 mL/min)
- Advanced liver disease
- History of lactic acidosis
- Pregnancy or breastfeeding
- Excessive alcohol consumption
- Before surgery or iodinated contrast imaging
Additionally, if your exercise routine includes regular strength training — and it should, if you care about longevity — evidence from the MASTERS and MET-PREVENT trials suggests metformin may reduce your muscle mass gains or fail to improve physical function when frailty is already present. This matters: sarcopenia is one of the strongest predictors of mortality in older adults.
Metformin in personalized longevity programs
In the context of current longevity medicine, metformin is considered a potential tool within a broader approach. It is not a magic pill, and no responsible physician prescribes it for longevity without first evaluating the patient's complete metabolic profile.
A personalized approach includes:
- Complete metabolic assessment: HbA1c, fasting insulin, HOMA-IR, postprandial glucose, lipid profile, body composition.
- Individual risk evaluation: family history, genetics (pharmacogenetics to predict drug response), current lifestyle.
- Risk-benefit balance: if you already have insulin resistance or prediabetes, the profile is favorable. If your metabolism is optimal and you strength train regularly, the benefit is questionable and the risk of exercise interference is real.
- Continuous monitoring: B12, kidney function, HbA1c, and body composition every 6-12 months.
Metformin, if used, should be combined with higher-evidence interventions: evidence-based nutrition, strength training, NAD+ optimization, sleep management, and chronic inflammation reduction.
The Progevita perspective: drugs, lifestyle, and integrated diagnostics
At Progevita we approach longevity from an integrative model. This means we do not dismiss pharmacological interventions when evidence supports them, but we also do not use them as shortcuts.
Our Optimization Program and Inflammaging Program combine advanced diagnostics — epigenetic clocks, bioimpedance, indirect calorimetry, VO₂max assessment, inflammatory markers, glucose and insulin markers — with medical review and a 12-month lifestyle plan. Metformin may have a place when the patient's metabolic profile justifies it, but never as a substitute for fundamentals: exercise, nutrition, sleep, and stress management.
If you want to explore whether your metabolic profile justifies considering metformin as part of a longevity plan, compare our longevity programs, review available diagnostics and treatments, or schedule an assessment with our medical team.
Frequently asked questions
Does metformin slow aging?
There is observational and preclinical evidence suggesting a geroprotective effect, but no clinical trials demonstrate this in healthy people. The TAME trial (still awaiting full funding) aims to answer this question definitively. What is proven is that metformin reduces mortality and complications in people with type 2 diabetes.
Can I take metformin to live longer if I do not have diabetes?
There is not enough evidence to recommend it. Observational studies have significant biases, and clinical trials in non-diabetic people have produced mixed or negative results. Additionally, metformin may interfere with strength training adaptations — an intervention with much stronger longevity evidence.
How much does metformin cost?
It is one of the cheapest drugs on the market. In Spain, the price with a prescription is between 3 and 10 euros per month. In the US, generic metformin costs between $4 and $15 per month. This is part of its appeal as a potential longevity intervention: if it worked, it would be accessible to almost everyone.
What are the most common side effects of metformin?
The most frequent are gastrointestinal: nausea, diarrhea, abdominal pain, and loss of appetite. They occur in 20-30% of users and typically improve after the first few weeks. Long-term use can also cause vitamin B12 deficiency (6-10% of patients), so monitoring levels is advisable.
How does metformin compare to rapamycin for longevity?
Rapamycin inhibits mTOR more directly and potently than metformin, and has more consistent results in animal models. However, its immunosuppressive effects are more pronounced, and its long-term safety profile in healthy people is less well known. Both drugs share activation of caloric-restriction-related pathways, but rapamycin is more advanced as a geroprotective candidate in the scientific literature.
Is metformin useful for weight loss?
It produces modest weight loss (about 2-3 kg on average after one year of use), but it is not a weight-loss drug. The effect is partially independent of glycemic improvement. If the goal is body composition, strength training and personalized nutrition are far more effective.
Conclusion
Metformin is a drug with an extensive clinical history, a reasonable safety profile, and real biological plausibility as a longevity tool. The molecular mechanisms are well described — AMPK, mTOR, inflammation, glucose metabolism — and converge on the same processes that the science of aging identifies as key drivers.
But evidence in healthy humans is limited. Observational data has biases. Clinical trials have produced mixed results. And the negative effect on muscle gain with exercise is a real drawback for active people.
If you have insulin resistance or prediabetes, metformin is an option with excellent backing. If your metabolism works well and your priority is longevity, the smartest move is to invest in what has solid evidence: strength training, anti-inflammatory nutrition, quality sleep, and a full diagnostic workup that tells you where you stand and where you need to go.
If you want to know where you stand, start here.
References
- Bannister CA et al. "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls." Diabetes Obes Metab. 2014. PMID: 25041462.
- Yang Y et al. "Metformin decelerates aging clock in male monkeys." Cell. 2024. PMID: 39270656.
- Barzilai N et al. "Targeting Aging with Metformin (TAME Trial): Design and Rationale." Cell Metab. 2016. PMID: 27667639.
- American Federation for Aging Research. "TAME - Targeting Aging with Metformin." Official trial resource. Accessed May 2026.
- Konopka AR et al. "Metformin inhibits mitochondrial respiration and decreases mTORC1 signaling in human skeletal muscle." Aging Cell. 2019. PMID: 30565871.
- Walton RG et al. "Metformin blunts muscle hypertrophy in response to resistance training." Aging Cell. 2019. PMID: 31267669.
- Witham MD et al. "Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT)." Lancet Healthy Longev. 2025;6(3):100695. PMID: 40147475. DOI: 10.1016/j.lanhl.2025.100695.
- Campbell JM et al. "Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control." Aging. 2017. PMID: 28489007.
- Keys AG et al. "Comparative safety of antidiabetic drugs on mortality in Denmark." Diabetes Care. 2022. PMID: 35749514.
- Zhou G et al. "Role of AMP-activated protein kinase in mechanism of metformin action." J Clin Invest. 2001. PMID: 11116012.
- "Emerging uncertainty on the anti-aging potential of metformin." Ageing Research Reviews. 2025. DOI: 10.1016/j.arr.2025.102607.